Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "Flucelvax Tetra" (27)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Influenza, Inactivated, Split Virus Or Surface Antigen (J07BB02) 27 products
WHO-DDD
DrugBank.ca
L
IP
V/S
Fluarix Tetra 15 µg / 0.5 ml
9.58
26.85
10 %
GlaxoSmithKline AG
B / SL
FB
G
L
IP
V/S
Influvac Tetra 0.5 ml
9.58
26.85
10 %
Viatris Pharma GmbH
B / SL
FB
G
L
IP
V/S
VaxigripTetra
9.58
26.85
10 %
Sanofi-Aventis
(Suisse) SA
B / SL
FB
G
IP
V/S
Flucelvax Tetra
9.58
26.85
10 %
Injection suspension: 3 Active Agents
Vifor (International) AG
B / SL
FB
G
L
IP
V/S
Efluelda 0.7 ml
31.00
48.80
10 %
suspension injectable en seringue préremplie: 3 Active Agents
Sanofi-Aventis
(Suisse) SA
B / SL
FB
G
IP
V/S
Fluarix Tetra 15 µg / 0.5 ml
10
PR
PR
k.A.
GlaxoSmithKline AG
B
FB
G
IP
V/S
Influvac Tetra 0.5 ml
10
PR
PR
k.A.
Viatris Pharma GmbH
B
FB
G
IP
V/S
VaxigripTetra
PR
PR
k.A.
Sanofi-Aventis
(Suisse) SA
B
FB
G
IP
V/S
VaxigripTetra
10
PR
PR
k.A.
Sanofi-Aventis
(Suisse) SA
B
FB
G
IP
V/S
VaxigripTetra
10
PR
PR
k.A.
Sanofi-Aventis
(Suisse) SA
B
FB
G
IP
V/S
Flucelvax Tetra
PR
PR
k.A.
Injection suspension: 3 Active Agents
Vifor (International) AG
B
FB
G
IP
V/S
Flucelvax Tetra
10
PR
PR
k.A.
Injection suspension: 3 Active Agents
Vifor (International) AG
B
FB
G
IP
V/S
Flucelvax Tetra
10
PR
PR
k.A.
Injection suspension: 3 Active Agents
Vifor (International) AG
B
FB
G
IP
V/S
Efluelda 0.7 ml
PR
PR
k.A.
suspension injectable en seringue préremplie: 3 Active Agents
Sanofi-Aventis
(Suisse) SA
B
FB
G
IP
V/S
Efluelda 0.7 ml
5
PR
PR
k.A.
suspension injectable en seringue préremplie: 3 Active Agents
Sanofi-Aventis
(Suisse) SA
B
FB
G
IP
V/S
Efluelda 0.7 ml
5
PR
PR
k.A.
suspension injectable en seringue préremplie: 3 Active Agents
Sanofi-Aventis
(Suisse) SA
B
FB
G
IP
V/S
Efluelda 0.7 ml
10
PR
PR
k.A.
suspension injectable en seringue préremplie: 3 Active Agents
Sanofi-Aventis
(Suisse) SA
B
FB
G
IP
V/S
Efluelda 0.7 ml
10
PR
PR
k.A.
suspension injectable en seringue préremplie: 3 Active Agents
Sanofi-Aventis
(Suisse) SA
B
FB
G
IP
V/S
Foclivia
PR
PR
k.A.
Vifor (International) AG
B
FB
G
IP
V/S
Foclivia
10
PR
PR
k.A.
Vifor (International) AG
B
FB
G
IP
V/S
Foclivia
10
PR
PR
k.A.
Vifor (International) AG
B
FB
G
L
IP
V/S
Influvac
Fertigspritze(n) à 0.5 ml
9.10
18.65
k.A.
Injection suspension: 3 Active Agents
Mylan Pharma GmbH
B / SL
FB
G
IP
V/S
Influvac
Fertigspritze(n) à 0.5 ml
9.10
18.65
k.A.
Mylan Pharma GmbH
B
FB
G
IP
V/S
Influvac
10 1 Fertigspritze(n) à 0.5 ml
PR
PR
k.A.
Mylan Pharma GmbH
B
FB
G
IP
V/S
Influvac
10 1 Fertigspritze(n) à 0.5 ml
PR
PR
k.A.
Injection suspension: 3 Active Agents
Mylan Pharma GmbH
B
FB
G
IP
V/S
Optaflu
0.5 ml
10.05
19.70
k.A.
Vaccinum Influenzae Inactivatum ex Corticis Antigeniis Praeparatum (Cellulae Mdck) 2015/2016
Novartis Pharma
Schweiz AG
B
FB
G
IP
V/S
Mutagrip
0.5 ml
8.51
17.95
k.A.
Vaccinum Influenzae-Split, Inactivatum 2018/2019
Sanofi-Aventis
(Suisse) SA
B
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home